CA2183331C - Procede de production d'un gel sterile de prednisolone - Google Patents
Procede de production d'un gel sterile de prednisolone Download PDFInfo
- Publication number
- CA2183331C CA2183331C CA002183331A CA2183331A CA2183331C CA 2183331 C CA2183331 C CA 2183331C CA 002183331 A CA002183331 A CA 002183331A CA 2183331 A CA2183331 A CA 2183331A CA 2183331 C CA2183331 C CA 2183331C
- Authority
- CA
- Canada
- Prior art keywords
- sterile
- polyacrylate
- gel
- prednisolone
- suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960005205 prednisolone Drugs 0.000 title claims abstract description 38
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims abstract description 31
- 229920000058 polyacrylate Polymers 0.000 claims abstract description 39
- 239000000725 suspension Substances 0.000 claims abstract description 18
- 150000002148 esters Chemical class 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 239000007900 aqueous suspension Substances 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 5
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical group [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 5
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 239000012929 tonicity agent Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 238000011146 sterile filtration Methods 0.000 claims description 3
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 239000008139 complexing agent Substances 0.000 claims 5
- 230000002335 preservative effect Effects 0.000 claims 5
- 239000008174 sterile solution Substances 0.000 claims 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- 239000008240 homogeneous mixture Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 10
- 239000000499 gel Substances 0.000 description 33
- 239000000243 solution Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 238000013019 agitation Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- 239000002674 ointment Substances 0.000 description 4
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960002800 prednisolone acetate Drugs 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 208000020564 Eye injury Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 150000001887 cortisones Chemical class 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Selon un procédé de production d'un gel stérile de prednisolone, on produit de manière connue en soi un gel stérile de polyacrylate, on stérilise la prednisolone ou ses esters pharmaceutiquement admissibles et on l'incorpore en quantités appropriées dans des conditions aseptiques au gel de polyacrylate, ou on met la prednisolone stérile ou ses esters en suspension dans une partie de la quantité d'eau requise pour produire la suspension de polyacrylate, on les incorpore de manière homogène au polyacrylate et on transforme ensuite celui-ci en un gel.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP4404990.0 | 1994-02-17 | ||
| DE4404990A DE4404990C1 (de) | 1994-02-17 | 1994-02-17 | Verfahren zur Herstellung eines sterilen Prednisolongels |
| PCT/EP1995/000155 WO1995022333A1 (fr) | 1994-02-17 | 1995-01-17 | Procede de production d'un gel sterile de prednisolone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2183331A1 CA2183331A1 (fr) | 1995-08-24 |
| CA2183331C true CA2183331C (fr) | 2006-12-12 |
Family
ID=37561034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002183331A Expired - Lifetime CA2183331C (fr) | 1994-02-17 | 1995-01-17 | Procede de production d'un gel sterile de prednisolone |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2183331C (fr) |
-
1995
- 1995-01-17 CA CA002183331A patent/CA2183331C/fr not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2183331A1 (fr) | 1995-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69818675T2 (de) | Galaktomannanpolymere und borat enthaltende augenarzneimittel | |
| EP1206281B1 (fr) | Formulation comprenant moxifloxacin et chlorure de sodium | |
| JPH07116029B2 (ja) | トラニラスト水溶液製剤 | |
| DE3320582A1 (de) | Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung | |
| JP2003513046A (ja) | フルオロキノロン抗生薬およびキサンタンガムを含有する薬学的組成物 | |
| EP0275457A2 (fr) | Solution contenant un chlorhydrate de lysozyme et du glycyrrhizinate dipotassique | |
| DE4139017A1 (de) | Waessrige piroxicam-loesungen und verfahren zu ihrer herstellung | |
| US5811417A (en) | Process for producing a sterile prednisolone gel | |
| DE69216831T2 (de) | Oxicam und oxicamderivate enthaltende ophthalmische zusammensetzungen | |
| JPS61143318A (ja) | 新規な製剤およびその調整方法 | |
| EP0233615B1 (fr) | Préparation aqueuse et son procédé de fabrication | |
| CA2183331C (fr) | Procede de production d'un gel sterile de prednisolone | |
| US5366985A (en) | Method for preparation of an aqueous suspension | |
| DE1177773B (de) | Traegersubstanz fuer pharmazeutische Produkte | |
| WO1993003723A1 (fr) | Complexe antagoniste de recepteur de leucotrienes-antihistamine | |
| JP2787131B2 (ja) | 水性懸濁液剤 | |
| JP2808378B2 (ja) | 水性懸濁液剤の製造法 | |
| CN1016313B (zh) | 治疗白内障的药物配方 | |
| WO2000056325A2 (fr) | Solution d'ibuprofene | |
| DE1944694C3 (de) | Pharmazeutische Zubereitung | |
| US4213963A (en) | Fluspirilene-containing compositions | |
| DE2546474A1 (de) | Injizierbares pharmazeutisches thyroxinpraeparat und verfahren zu dessen herstellung | |
| DE60106619T2 (de) | Pharmazeutische zusammensetzungen enthaltend tobramycin und xanthangummi | |
| EP0770383B1 (fr) | Gel ophtalmique à base de cromolyn | |
| US3780176A (en) | Predominantly aqueous substituted triamcinolone compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20150119 |